Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
出版年份 2014 全文链接
标题
Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 112, Issue 1, Pages 103-111
出版商
Springer Nature
发表日期
2014-10-29
DOI
10.1038/bjc.2014.556
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast
- (2015) Mu-Min Shao et al. HISTOPATHOLOGY
- Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer
- (2014) Hee Jin Lee et al. BREAST CANCER RESEARCH AND TREATMENT
- High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
- (2014) Heae Surng Park et al. MODERN PATHOLOGY
- Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
- (2013) W. J. Gradishar ANNALS OF ONCOLOGY
- Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer
- (2013) Alessandra Fabi et al. EXPERT OPINION ON PHARMACOTHERAPY
- EGFRGene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
- (2013) Won Hwangbo et al. Korean Journal of Pathology
- Role of epidermal growth factor receptor in breast cancer
- (2012) Hiroko Masuda et al. BREAST CANCER RESEARCH AND TREATMENT
- Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
- (2012) A Gallardo et al. BRITISH JOURNAL OF CANCER
- Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful
- (2012) Maialen Martin-Arruti et al. HISTOPATHOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer
- (2011) G. Somlo et al. BREAST CANCER RESEARCH AND TREATMENT
- Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations
- (2011) Ning Lv et al. Diagnostic Pathology
- EGFR expression and gene copy number in triple-negative breast carcinoma
- (2010) Berrak Gumuskaya et al. CANCER GENETICS AND CYTOGENETICS
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. Journal of Oncology Practice
- EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
- (2009) S. Gori et al. ANNALS OF ONCOLOGY
- A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
- (2008) C. L. Arteaga et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started